Fabio Bastos Russomano

Dr. Fabio Bastos Russomano

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2018 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
LZLuiz Carlos Zeferino
Luiz Carlos Zeferino
JBJoana Bragança Bastos
Joana Bragança Bastos
DVDiama Bhadra Vale
Diama Bhadra Vale
RZRita Maria Zanine
Rita Maria Zanine
YMYara Lucia Mendes Furtado de Melo
Yara Lucia Mendes Furtado de Melo
FRFabio Bastos Russomano
Fabio Bastos Russomano
Evidence-based clinical guidelines ensure best practice protocols are available in health care. There is a widespread use of human papillomavirus deoxyribonucleic acid (HPV-DNA) tests in Brazil, regardless of the lack of official guidelines. On behalf of the Brazilian Association for the Lower Genital Tract Pathology and Colposcopy (ABPTGIC, in the Portuguese acronym), a team of reviewers searched for published evidence and developed a set of recommendations for the use of HPV-DNA tests in cervical cancer screening in Brazil. The product of this process was debated and consensus was sought by the participants. One concern of the authors was the inclusion of these tests in the assessment of women with cytologic atypia and women treated for cervical intraepithelial neoplasia (CIN). Testing for HPV is recommended in an organized screening scenario to identify women with precursor lesions or asymptomatic cervical cancer older than 30 years of age, and it can be performed every 5 years. It also has value after the cytology showing atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSILs) as a triage test for colposcopy, in the investigation of other cytological alterations when no abnormal findings are observed at colposcopy, seeking to exclude disease, or, further, after treatment of high-grade cervical intraepithelial neoplasia, to rule out residual disease.

1 January 2019 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
CRCaroline Madalena Ribeiro
Caroline Madalena Ribeiro
MDMaria Beatriz Kneipp Dias
Maria Beatriz Kneipp Dias
MPMaria Asunción Sole Pla
Maria Asunción Sole Pla
FCFlávia Miranda Correa
Flávia Miranda Correa
FRFabio Bastos Russomano
Fabio Bastos Russomano
JTJeane Glaucia Tomazelli
Jeane Glaucia Tomazelli
Estimaram-se parâmetros para planejamento e programação da oferta de procedimentos para rastreamento, investigação diagnóstica e tratamento de lesões precursoras do câncer do colo do útero e, com base nessas estimativas, avaliou-se a adequação da produção nacional dos procedimentos realizados pelo Sistema Único de Saúde (SUS) em 2017. As estimativas foram calculadas utilizando como referencial as condutas preconizadas nas diretrizes nacionais para o rastreamento. Os dados referentes aos exames de rastreamento foram obtidos no Sistema de Informação do Câncer do Colo do Útero, e os dados de seguimento, em prontuários médicos de uma unidade de referência em patologia cervical. A produção nacional dos procedimentos foi obtida a partir de dados dos Sistemas de Informações Ambulatoriais e Hospitalares do SUS. Para cada cem mil mulheres na faixa etária alvo do rastreamento (25-64 anos), estimou-se a necessidade anual de 44.134 exames citopatológicos, 1.886 colposcopias, 275 biópsias, 236 excisões tipo 1 e 2 ambulatoriais, 236 excisões tipo 2 e 3 hospitalares e 39 encaminhamentos para alta complexidade para realização de cirurgia, quimioterapia e/ou radioterapia. Aplicando-se os parâmetros estimados ao número de mulheres rastreadas no Brasil em 2017, identificou-se déficit de todos os procedimentos para o seguimento adequado das mulheres com alterações, variando de 7% nas colposcopias a 74% nas excisões tipo 3. Os resultados apontam necessidade de ampliar e qualificar a oferta de procedimentos da linha de cuidado do câncer do colo do útero. Os parâmetros estimados poderão subsidiar gestores na programação e implementação de programas de rastreamento organizado.

1 January 2023 in Physis: Revista de Saúde Coletiva
Verified
Journal Article
Open access
PDF file
AEAline Piovezan Entringer
Aline Piovezan Entringer
ASAna Lúcia Tiziano Sequeira
Ana Lúcia Tiziano Sequeira
FRFabio Bastos Russomano
Fabio Bastos Russomano
KSKátia Sydrônio
Kátia Sydrônio
CNCarolina de Oliveira Nogueira
Carolina de Oliveira Nogueira
MPMárcia Pinto
Márcia Pinto
Resumo O objetivo do estudo foi estimar o custo da implantação de um centro de reprodução humana em um hospital público de referência nacional localizado no Rio de Janeiro. A população elegível foi a de homens e mulheres que possuem diagnóstico das causas mais frequentes de infertilidade. Os itens de custos incluídos foram consultas, exames, equipamentos, recursos humanos e insumos. Os custos foram identificados e quantificados a partir de consulta a clínicas de reprodução assistida, especialistas e literatura. Foram valorados através de bases públicas. A análise dos dados foi realizada através de um modelo de decisão analítico. A perspectiva do estudo foi do SUS provedor. O custo por procedimento na alta complexidade foi de R$ 18.829 para a fertilização in vitro com injeção intracitoplasmática de espermatozoide e de R$ 5.649 para a inseminação artificial. O investimento inicial necessário para funcionamento do centro de alta complexidade para a realização de 480 ciclos foi de R$ 15.903.361 no primeiro ano, o qual incluiu a estruturação do ambiente físico. A estimativa do investimento necessário para a incorporação e manutenção dos serviços no SUS é indispensável para a gestão financeira.

8 October 2015 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
NKNina de Siqueira Kuperman
Nina de Siqueira Kuperman
FRFabio Bastos Russomano
Fabio Bastos Russomano
YMYara Lucia Mendes Furtado de Melo
Yara Lucia Mendes Furtado de Melo
SGSaint Clair dos Santos GomesJr
Saint Clair dos Santos GomesJr
Cervical cancer is the third most common cancer in Brazil and has a high potential for prevention and cure. The prevalence of invasive and preinvasive disease in women with cytological diagnosis of high-grade lesion – cannot exclude microinvasion (HSIL-micro) is not known. This cross-sectional study used a cytology lab database to identify women with HSIL-micro and HSIL referred to two colposcopic units from June 2006 to December 2012. For each woman with HSIL-micro, four women with cytologic diagnosis of HSIL who met the inclusion criteria were identified. Data were obtained from review of medical records. Forty-seven patients with report of HSIL-micro and 188 patients with report of HSIL were included. The final diagnoses revealed a frequency of preinvasive lesions of 31.9 % (15/47) and 59.6 % (112/188) in patients with HSIL-micro and HSIL, respectively, while the frequency of invasive disease was 63.8 % (30/47) and 11.7 % (22/188), respectively. The HSIL-micro group showed prevalence of preinvasive or invasive disease 6.5 times greater (95 % CI = 1.6-5.7) and, for invasive disease, 2.4 times greater (95 % CI = 1.7-3.6) than the HSIL group. Higher risk of preinvasive and invasive lesions in women with cytologic diagnosis of HSIL-micro reinforces recommendations for immediate investigation.

1 February 2020 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
PJPaula Moskovics Jordão
Paula Moskovics Jordão
FRFabio Bastos Russomano
Fabio Bastos Russomano
GGGabriella Tostes Gerbauld
Gabriella Tostes Gerbauld
CACecília Vianna de Andrade
Cecília Vianna de Andrade
COClarice Fraga Esteves Maciel Osorio
Clarice Fraga Esteves Maciel Osorio
BACKGROUND: Cervical cancer screening in Brazil is done using Pap smears. Women who are most likely to have a preinvasive lesion or cervical cancer are immediately referred for colposcopy. OBJECTIVE: The aim of this study was to evaluate the diagnostic performance of endocervical cytological tests in diagnosing preinvasive cervical lesions in women with initial high-grade squamous intraepithelial lesions (HSIL), or atypical squamous cells in which high-grade lesions could not be ruled out (ASC-H), or atypical glandular cells (AGC), and whose colposcopy did not show any abnormalities, with no fully visible transformation zone (types 2 and 3). DESIGN AND SETTING: Retrospective observational study conducted in Rio de Janeiro, Brazil. METHODS: Data from women who came to the cervical pathology outpatient clinic between January 2012 and April 2017 were analyzed. The results from endocervical cytological tests were compared with the final diagnosis, which was obtained through examination of a surgical specimen or, among women who did not undergo an excisional procedure, after cytological and colposcopic follow-up for two years. RESULTS: We included 78 women. The sensitivity of endocervical cytological tests was 72.7%; specificity 98.5%; positive and negative predictive values 88.9% and 95.6%, respectively; and positive and negative likelihood ratios 48.7 and 0.28. CONCLUSION: Endocervical cytological tests are simple, inexpensive and noninvasive, and form a reliable method for determining management among patients with HSIL, ASC-H and AGC cytological findings and negative colposcopic findings without visualization of the squamocolumnar junction.

1 January 2024 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
AFAmanda Leal Ferreira
Amanda Leal Ferreira
NDNasle Domingues Dibe
Nasle Domingues Dibe
BPBruna Rodrigues de Paiva
Bruna Rodrigues de Paiva
EAElyzabeth Avvad-Portari
Elyzabeth Avvad-Portari
DDDione Corrêa de Araújo Dock
Dione Corrêa de Araújo Dock
CACecília Vianna de Andrade
Cecília Vianna de Andrade
Managing cervical intraepithelial neoplasia grade 2 (CIN2) is challenging, considering the CIN2 regression rate, perinatal risks associated with excisional procedures, and insufficient well-established risk factors to predict progression.